News | October 10, 2025
Delhi High Court refuses to restrain Natco from manufacturing spinal muscular atrophy drug
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
NATCO is the first company in India to have received its registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
Subscribe To Our Newsletter & Stay Updated
